Smart Diagnostics: Combining Artificial Intelligence and In Vitro Diagnostics

• Published in: Sensors (Basel, Switzerland) Vol. 22; no. 17; p. 6355
• Main Authors: McRae, Michael P., Rajsri, Kritika S., Alcorn, Timothy M., McDevitt, John T.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.08.2022; MDPI
• Subjects: Algorithms; Artificial Intelligence; Biological markers; Biomarkers; Biosensing Techniques; Cardiovascular disease; Care and treatment; Chronic obstructive pulmonary disease; Computer-aided medical diagnosis; Coronaviruses; Costs; COVID-19; COVID-19 - diagnosis; COVID-19 Testing; cytology; Health aspects; Heart attacks; Heart failure; Humans; Identification and classification; Immunoassay; in vitro diagnostics; Kinases; lab on a chip; Medical equipment; Methods; Microfluidics; Oral cancer; Pandemics; Patients; point of care; Point-of-Care Systems; Software; Substance abuse treatment; Testing laboratories; China; cytology; lab on a chip; clinical decision support tool; in vitro diagnostics; point of care; artificial intelligence; immunoassay
• ISSN: 1424-8220; 1424-8220
• DOI: 10.3390/s22176355

We are beginning a new era of Smart Diagnostics—integrated biosensors powered by recent innovations in embedded electronics, cloud computing, and artificial intelligence (AI). Universal and AI-based in vitro diagnostics (IVDs) have the potential to exponentially improve healthcare decision making in the coming years. This perspective covers current trends and challenges in translating Smart Diagnostics. We identify essential elements of Smart Diagnostics platforms through the lens of a clinically validated platform for digitizing biology and its ability to learn disease signatures. This platform for biochemical analyses uses a compact instrument to perform multiclass and multiplex measurements using fully integrated microfluidic cartridges compatible with the point of care. Image analysis digitizes biology by transforming fluorescence signals into inputs for learning disease/health signatures. The result is an intuitive Score reported to the patients and/or providers. This AI-linked universal diagnostic system has been validated through a series of large clinical studies and used to identify signatures for early disease detection and disease severity in several applications, including cardiovascular diseases, COVID-19, and oral cancer. The utility of this Smart Diagnostics platform may extend to multiple cell-based oncology tests via cross-reactive biomarkers spanning oral, colorectal, lung, bladder, esophageal, and cervical cancers, and is well-positioned to improve patient care, management, and outcomes through deployment of this resilient and scalable technology. Lastly, we provide a future perspective on the direction and trajectory of Smart Diagnostics and the transformative effects they will have on health care.